Cell Source to Present at the Roth Capital Conference in Dana Point, CA on March 10, 2015
TEL AVIV, ISRAEL / ACCESSWIRE / March 9, 2015 / Cell Source, Inc. (CLCS) ("Cell Source") an immunotherapy and regenerative medicine company, announced today its President and CEO, Itamar Shimrat, will present at the Roth Conference on Tuesday, March 10, 2015 at 5:30pm in Dana Point, California.
The Roth Capital Conference is among the premier annual micro-cap conferences in the United States. The conference is an exclusive gathering of the "Who's who" of the micro-cap space, with a lineup of industry leaders, standout companies and cutting edge speakers and panelists.
For further information, please visit www.cell-source.com or contact Itamar Shimrat, President & CEO (646) 416-7896.
About The Roth Conference
Roth Capital is an investment banking firm dedicated to the small-cap public market. Since its inception in 1984, ROTH has been an innovator in this market. Headquartered in Newport Beach, CA, Roth has regional offices in Boston, Chicago, Larkspur, Los Angeles, New York and San Diego as well as Hong Kong. Roth is hosting its 27th annual micro-cap Conference. This invitation-only event attracts hundreds of high net worth investors and financial leaders. The Conference will be a unique gathering featuring the "Who's who" of the micro-cap investment world.
About Cell Source, Inc.
Cell Source is an immunotherapy and regenerative medicine company whose primary breakthrough is the regulation of immune tolerance. In preclinical studies Cell Source's therapies have demonstrated the ability to directly address a number of severe medical conditions including blood cancers such as non-Hodgkins lymphoma, multiple myeloma, and chronic lymphocytic leukemia. Cell Source's organ regeneration platform holds the potential to repair organs and to grow entire organs inside the patient's body. Growing or regenerating organs and using cell therapy to tolerize the immune system can each revolutionize the treatment of numerous severe diseases that today kill hundreds of thousands of patients annually.
SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION ACT OF 1995
With the exception of historical information, the matters discussed in this news release are forward-looking statements that involve a number of risks and uncertainties. The actual future results of Cell Source could differ significantly from those statements. Factors that could cause actual results to differ materially include risks and uncertainties such as the inability to finance the company's operations, inability to hire and retain qualified personnel, and changes in the general economic climate. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "expect," "plan," "anticipate," "believe," "estimate," "predict," "potential" or "continue," the negative of such terms, or other comparable terminology. These statements are only predictions. Although we believe that the expectations reflected in the forward-looking statements are reasonable, such statements should not be regarded as a representation by Cell Source, or any other person, that such forward-looking statements will be achieved. We undertake no duty to update any of the forward-looking statements, whether as a result of new information, future events or otherwise. In light of the foregoing, readers are cautioned not to place undue reliance on such forward-looking statements. This release does not constitute an offer to sell or a solicitation of offers to buy any securities of any entity.
SOURCE: Cell Source, Inc.